Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
apatolimab + tovotulimumab
- Development stage
- Unknown
- Lead developer
- Qilu Pharmaceutical
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Apatolimab + tovotulimumab is an investigational combination therapy, potentially administered as a bispecific antibody (Apatolimab-Tovotulimumab), targeting both the angiogenic and immune checkpoint pathways. Apatolimab is a humanized monoclonal antibody directed against the vascular endothelial growth factor receptor 2 (VEGFR2), while tovotulimumab is a human monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor. This combination is intended to treat advanced malignancies, specifically hepatocellular carcinoma (HCC), by simultaneously inhibiting tumor vascularization and restoring T-cell mediated anti-tumor activity. It has been studied in clinical trial settings (e.g., ChiCTR2600123451) in combination with lenvatinib for patients who have progressed on standard-of-care PD-1 inhibitors and bevacizumab.
- Other names
- Apatolimab-Tovotulimumab
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on apatolimab + tovotulimumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on apatolimab + tovotulimumab.